Bruker Corporation reported first-quarter 2026 results on May 6, posting revenue of $823.4 million, up 2.7% year-on-year. The headline number masks an organic decline of 4.4%, with a 4.5% foreign-exchange tailwind and 2.6% from acquisitions doing the heavy lifting. GAAP diluted EPS came in at $0.02, down from $0.11 a year ago; non-GAAP diluted EPS was $0.31, against $0.47 in Q1 2025. Non-GAAP operating margin compressed to 10.2% from 12.7%.
The Bruker Scientific Instruments (BSI) segment, which houses BioSpin, CALID, and Nano, generated $759.8 million, up 2.1% reported and down 5.0% organically. CALID, the unit that includes Bruker Optics and the company’s process and laboratory FT-IR and FT-NIR analyzer lines alongside mass spectrometry, was the largest sub-segment at $316.3 million. BioSpin contributed $197.5 million and Nano $246.0 million. The smaller Bruker Energy & Supercon Technologies (BEST) segment grew 12.8% to $66.9 million, with 3.0% organic. Regionally, Europe was up 12.8% on a reported basis - mostly FX - while Asia Pacific fell 10.2%, consistent with the broader China-academic weakness flagged by peers earlier this earnings season.
CEO Frank H. Laukien said BSI bookings “grew organically at a high single digit percentage” and that BSI’s book-to-bill ratio stayed above 1.0x for a third consecutive quarter, with order strength concentrated in semiconductor metrology, SciY laboratory software, industrial research tools, and security detection. The company reconfirmed full-year 2026 guidance of $3.57 to $3.60 billion in revenue, 1-2% organic growth, and non-GAAP EPS of $2.10 to $2.15.
For process-analytics buyers, the Q1 segment file does not disaggregate Bruker Optics from CALID’s mass-spec line, so the print does not directly inform inline FT-NIR or FT-IR pricing. The signal that does carry over is the bookings trajectory: a third quarter of book-to-bill above 1.0x suggests instrument-line backlog is rebuilding, which historically tightens lead times for new orders. Buyers benchmarking process FT-NIR against Raman alternatives should treat the headline organic decline as an academic and China-Pacific story rather than a read-through on industrial PAT spending, which segment-level reporting does not isolate. Peer prints from Thermo Fisher and Mettler-Toledo earlier this cycle pointed in the same direction.